Potent anti-inflammatory/analgesic effects of lornoxicam in comparison to other nsaids: A c-fos study in the rat

Buritova, Jaroslava; Besson, Jean‐Marie

doi:10.1007/s10787-997-0030-9

Cited by 9 publications

(6 citation statements)

References 37 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Signi®cance compared to control carrageenan group was performed using ANOVA and Fisher's PLSD test (*P50.05, **P50.01, ***P50.001). the doses in the same range of other intravenously preadministered NSAIDs under carrageenan in¯ammation (50 ± 70% reduction of the total number of spinal c-Fos-LI neurons; see references in Buritova & Besson, 1997a. The correlations between the e ects of intravenous racemicor S(+)-¯urbiprofen on the spinal c-Fos protein expression and the peripheral oedema suggest a predominant peripheral site of action of these compounds with a subsequent reduction of nociceptive inputs to the spinal cord and thus a decrease in carrageenan-evoked spinal c-Fos protein expression.…”

Section: Discussionmentioning

confidence: 99%

“…Flurbiprofen enantiomers, spinal c-Fos expression and inflammation 95 J. Buritova & J.-M. Besson the doses in the same range of other intravenously preadministered NSAIDs under carrageenan in¯ammation (50 ± 70% reduction of the total number of spinal c-Fos-LI neurons; see references in Buritova & Besson, 1997a.…”

Section: Figure 7 Camera Lucida Drawings Of Individual Representativmentioning

confidence: 99%

“…Results are expressed as % of the control value for the total number of c-Fos-LI neurons and their number in each region (+ s.e.m.). Statistical comparisons between the e ects of S(+)-¯urbiprofen versus R(7)-¯urbiprofen were performed using ANOVA and Fisher's PLSD test (#P50.05, ##P50.01, ###P50.001).Flurbiprofen enantiomers, spinal c-Fos expression and inflammation 95 J. Buritova & J.-M. Besson the doses in the same range of other intravenously preadministered NSAIDs under carrageenan in¯ammation (50 ± 70% reduction of the total number of spinal c-Fos-LI neurons; see references in Buritova & Besson, 1997a.The correlations between the e ects of intravenous racemicor S(+)-¯urbiprofen on the spinal c-Fos protein expression and the peripheral oedema suggest a predominant peripheral site of action of these compounds with a subsequent reduction of nociceptive inputs to the spinal cord and thus a decrease in carrageenan-evoked spinal c-Fos protein expression. To con®rm this assertion we have evaluated the e ects of intraplantar injection of the racemic-or S(+)-¯urbiprofen.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Peripheral and/or central effects of racemic‐, S(+)‐ and R(−)‐flurbiprofen on inflammatory nociceptive processes: a c‐Fos protein study in the rat spinal cord

Buritova

Besson

1998

British J Pharmacology

View full text Add to dashboard Cite

1 We have evaluated the e ects of intravenous or intraplantar racemic-, S(+)-and R(7)-¯urbiprofen on both the carrageenan-evoked peripheral oedema and spinal c-Fos immunoreactivity, an indirect index of neurons involved in spinal nociceptive processes. 2 Three hours after intraplantar injection of carrageenan (6 mg in 150 ml of saline) in awake rats, a peripheral oedema and numerous c-Fos protein-like immunoreactive (c-Fos-LI) neurons in L4 ± L5 segments were observed. c-Fos-LI neurons were essentially located in the super®cial (I ± II) and deep (V ± VI) laminae of the dorsal horn. 3 Intravenous racemic-¯urbiprofen (0.3, 3 and 9 mg kg 71 ) dose-relatedly reduced the carrageenanevoked oedema and spinal c-Fos expression (r=0.64, r=0.88 and r=0.84 for paw diameter, ankle diameter and number of c-Fos-LI neurons; P50.05, P50.001 and P50.001 respectively).4 Similar e ects to those of intravenous racemic-¯urbiprofen were obtained with intravenous S(+)-urbiprofen (0.3, 3 and 9 mg kg 71 ) which dose-relatedly reduced the number of c-Fos-LI neurons (r=0.69, P50.01) and diameters of paw and ankle (r=0.56 and r=0.52 respectively, P50.05 for both). 5 For the dose of 0.3 mg kg 71 i.v., R(7)-¯urbiprofen did not modify the number of c-Fos-LI neurons and produced a weak reduction of oedema at only the ankle level (23+12% reduction, P50.05). However, a ten times higher dose of R(7)-¯urbiprofen (3 mg kg 71 i.v.) was necessary to obtain e ects comparable to those of S(+)-or racemic-¯urbiprofen (0.3 mg kg 71 i.v.). 6 Intraplantar racemic-¯urbiprofen (1, 10 and 30 mg) dose-relatedly reduced the carrageenan-enhanced ankle diameter (r=0.81, P50.001) and the number of c-Fos-LI neurons in L4 ± L5 segments (r=0.83, P50.001), with a 60+3% reduction of the number of c-Fos-LI neurons (P50.001), and 30+3 and 67+7% reduction of paw and ankle diameter respectively (P50.001 for both) for the dose of 30 mg. 7 For intraplantar S(+)-¯urbiprofen (1, 10 and 30 mg) the dose-related e ects (r=0.77, r=0.60 and r=0.59 for c-Fos-LI neurons, paw and ankle diameters respectively, P50.001, P50.01 and P50.01) were similar to those of racemic-¯urbiprofen. In contrast, intraplantar R(7)-¯urbiprofen (1, 10 and 30 mg) did not have detectable e ects on all studied parameters. 8 The present study provides clear evidence for potent anti-in¯ammatory and antinociceptive e ects of both intravenous or intraplantar racemic-and S(+)-¯urbiprofen. These results further demonstrate marked anti-in¯ammatory and antinociceptive e ects of intravenous, but not intraplantar, R(7)-urbiprofen. These results suggest that the main site of action of racemic-and S(+)-¯urbiprofen is in the periphery and indicate that the site of action of R(7)-¯urbiprofen is mainly of central origin. Keywords: Carrageenan in¯ammation; c-Fos; dorsal horn; racemic-¯urbiprofen; S(+)-¯urbiprofen; R(7)-¯urbiprofen; nociception; NSAIDs; rat IntroductionFlurbiprofen is a member of the 2-arylpropionic acid (2-APA) class, also known as profens, an important group of nonsteroidal anti-in¯ammatory drugs (NSAIDs); f...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Figure 7 Camera Lucida Drawings Of Individual Representativmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Peripheral and/or central effects of racemic‐, S(+)‐ and R(−)‐flurbiprofen on inflammatory nociceptive processes: a c‐Fos protein study in the rat spinal cord

Buritova

Besson

1998

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…Its analgesic activity is comparable to that of opioids. High therapeutic potency is indicated in low doses, with a reduced risk of side eff ects (6)(7)(8). Preliminary research, which requires further confi rmation, suggest that lornoxicam may be a better alternative or adjunctive therapy to opioid analgesics in the treatment of moderate to severe pain (9,10).…”

Section: Research Articlementioning

confidence: 99%

The synergistic antinociceptive effect of lornoxicam in combination with tramadol

Saračević

Bečić

2013

JHSCI

View full text Add to dashboard Cite

Introduction:One of the most important priorities in therapy is pain control. Therefore, many different groups of drugs are being used for this purpose, primarily opioid analgesics and non-steroidal anti-infl ammatory drugs (NSAIDs). Opioid analgesic tramadol, by binding to specifi c receptors, modulates the perception and response to painful stimuli and inhibits transmitting and further processing of pain impulses. Lornoxicam, which belongs to the oxicam class of NSAIDs, is a non-selective cyclooxygenase inhibitor with strong analgesic and anti-infl ammatory effects, and better tolerance profi le. Preliminary research, which requires further verifi cation, suggests that lornoxicam may be a better alternative or adjunctive therapy to opioid analgesics in the treatment of moderate to severe pain. The aim of this study was to investigate antinociceptive effects of lornoxicam, as well as the combination of lornoxicam with tramadol.Methods: Analgesic effect of combination of lornoxicam and tramadol or lornoxicam applied alone was examined on female albino mice, using a hot plate method. Measurements were made 30, 60, 90 and 120 minutes after intraperitoneal and subcutaneous administration, in dose of 10 mg/kg. Results:Combination of lornoxicam and tramadol, applied intraperitoneally, increases the threshold of sensitivity to painful stimuli, which was not the case with subcutaneous administration. Conclusions:Lornoxicam signifi cantly increases analgesic effect when applied intraperitoneally in combination with tramadol. On the other hand, lornoxicam in combination with tramadol, did not increase the threshold of sensitivity to painful stimuli with signifi cant difference, after subcutaneous administration.

show abstract

“…Lornoxicam (chlortenoxicam) is a type of oxicams with analgesic, anti-inflammatory, and antipyretic properties mainly mediated by the inhibition of prostaglandins, with a better tolerance due to the relatively shorter elimination half-life in comparison to other members of the oxicams class [12][13][14][15][16]. In addition, the inhibitory potential of lornoxicam on in vitro prostaglandin synthesis in rat neutrophils was found 100-fold more than tenoxicam and prevented the arachidonic acid-induced lethality in mice more efficiently than indomethacin or piroxicam [12,15,17].…”

Section: Introductionmentioning

confidence: 99%

Immunomodulatory Effects of the Cyclooxygenase Inhibitor Lornoxicam on Phenotype and Function of Camel Blood Leukocytes

Hussen

Kandeel

Shawaf

et al. 2021

Animals

View full text Add to dashboard Cite

(1) Background: Lornoxicam is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, antiphlogistic and antipyretic effects. The improved tolerance of lornoxicam due to the relatively shorter elimination half-life in comparison to other members of the oxicams may favor its application in the management of pain and inflammation in race dromedary camels. There are no studies conducted yet on the immunomodulatory or immunotoxilogic effect of lornoxicam in camels. Therefore, the current study aimed to evaluate the immunomodulatory effects of the cyclooxygenase inhibitor lornoxicam on some phenotypic and functional properties of camel blood leukocytes; (2) Methods: Using flow cytometry, blood leukocyte composition, monocyte phenotype, and antimicrobial functions of neutrophils and monocytes were analyzed ex vivo after a single dose injection with lornoxicam. In addition, the effect of in vitro incubation of camel blood with lornoxicam on leukocyte cell vitality and antimicrobial functions were evaluated; (3) Results: The injection of camels with a single dose of lornoxicam resulted in a significant change in their leukogram with reduced numbers of total leukocytes, neutrophils, eosinophils, monocytes, and lymphocytes. Within the lymphocyte population, the numbers of CD4+ T cells, γδ T cells, and B cells decreased significantly in blood after injection of camels with lornoxicam. In addition, injection of lornoxicam resulted in decreased abundance of major histocompatibility complex (MHC) class II molecules and increased abundance of the scavenger receptor CD163 on blood monocytes, indicating an anti-inflammatory phenotype of monocytes. Functionally, administration of lornoxicam decreased the capacity of camel neutrophils and monocytes to uptake bacteria and to produce reactive oxygen species (ROS) after bacterial stimulation. Similarly, the in vitro whole blood incubation with lornoxicam resulted in reduced phagocytosis and ROS production activity of the camel blood phagocytes. Flow cytometric analysis of cell vitality, including cell necrosis and apoptosis, revealed a pro-apoptotic effect of lornoxicam on camel leukocytes; (4) Conclusions: Lornoxicam administration, at the dose and intervals utilized herein, induces significant changes in the phenotype and function of camel blood leukocytes. The reduced cell numbers of all studied leukocyte subpopulations in lornoxicam-treated camels, which seems to be a result of enhanced cell apoptosis, indicates an inhibitory effect rather than a modulatory effect of lornoxicam on the camel immune system, which need to be considered when using lornoxicam in camel medicine.

show abstract

Potent anti-inflammatory/analgesic effects of lornoxicam in comparison to other nsaids: A c-fos study in the rat

Cited by 9 publications

References 37 publications

Peripheral and/or central effects of racemic‐, S(+)‐ and R(−)‐flurbiprofen on inflammatory nociceptive processes: a c‐Fos protein study in the rat spinal cord

Peripheral and/or central effects of racemic‐, S(+)‐ and R(−)‐flurbiprofen on inflammatory nociceptive processes: a c‐Fos protein study in the rat spinal cord

The synergistic antinociceptive effect of lornoxicam in combination with tramadol

Immunomodulatory Effects of the Cyclooxygenase Inhibitor Lornoxicam on Phenotype and Function of Camel Blood Leukocytes

Contact Info

Product

Resources

About